Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine versus standard care for craving and lapse in methamphetamine dependence
IRCT20260919071103N1Phase 3Recruiting
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atomoxetine in methamphetamine use disorder (MUD) (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Craving reduction and Lapse. Started Oct 2026; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20260919071103N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260919071103N1.